Probability of commercial success is different from probability of clinical success.
Atebion BDS believes that early commercial insight to a disease target product proﬁle (DTPP) or a candidate’s target proﬁle (TPP) is a prerequisite for success, whether this relates to completing an in- or out-license or a successful product launch.
High quality techno-commercial evaluations represent a core component of all our services.
Evaluations from Atebion BDS provide the following components;
Disease area overview
- Clinical need and its evolution
- Leading drugs and profiles
- Key success factors and barriers to success
- Regional needs and differences
Pipeline assessment and competitive landscape
Sales and forecasts
- WW. by Region and/or key market
S&M approaches and costs
- Current and evolving